Chapter 11
Personalized Polypills Produced by Fused Deposition Modeling 3D Printing
Sheng Qi,
Jehad Nasereddin,
Fahad Alqahtani,
Sheng Qi
University of East Anglia, School of Pharmacy, Earlham Road, Norwich,, NR4 7TJ UK
Search for more papers by this authorJehad Nasereddin
University of East Anglia, School of Pharmacy, Earlham Road, Norwich,, NR4 7TJ UK
Search for more papers by this authorFahad Alqahtani
University of East Anglia, School of Pharmacy, Earlham Road, Norwich,, NR4 7TJ UK
Search for more papers by this authorSheng Qi,
Jehad Nasereddin,
Fahad Alqahtani,
Sheng Qi
University of East Anglia, School of Pharmacy, Earlham Road, Norwich,, NR4 7TJ UK
Search for more papers by this authorJehad Nasereddin
University of East Anglia, School of Pharmacy, Earlham Road, Norwich,, NR4 7TJ UK
Search for more papers by this authorFahad Alqahtani
University of East Anglia, School of Pharmacy, Earlham Road, Norwich,, NR4 7TJ UK
Search for more papers by this authorBook Editor(s):Mohammed Maniruzzaman,
Mohammed Maniruzzaman
School of Life Sciences, University of Sussex, Brighton, UK, BN1 9QG
Search for more papers by this authorSummary
Personalized medicine in the literature commonly refers to using patient's genetic information to enable therapeutic decisions tailored to an individual patient. Personalized pills containing more than one drug are referred as polypills, which is a term exclusively used in the treatment of cardiovascular diseases (CVD) in the literature, but the usage is expanded to cover a range of pills that combine many medicines to provide a single solid dosage form that allows the patients to self-administer easily. Polypharmacy is used in the medical literature to describe the co-administration of multiple medications to patients who may have multiple comorbidities. There are a number of critical process parameters (CPPs) controlling the quality of fused deposition modeling (FDM) 3D printing. Two common methods of preparing drug-loaded filaments have been reported in the pharmaceutical literature: impregnation and extrusion. It has been widely recognized that FDM 3D printing has unique advantages for fabricating personalized polypills.
References
- Norman, J., Madurawe, R.D., Moore, C.M.V. et al. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews 108: 39–50.
- Pan, F., Chernew, M.E., and Mark Fendrick, A. (2008). Impact of fixed-dose combination drugs on adherence to prescription medications. Journal of General Internal Medicine 23 (5): 611–614.
- US-FDA (2013). Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development. Washington, DC: US Department of Health and Human Services.
-
Ursan, I.D., Chiu, L., and Pierce, A. (2013). Three-dimensional drug printing: a structured review. Journal of the American Pharmacists Association (2003)
53 (2): 136–144.
10.1331/JAPhA.2013.12217 Google Scholar
- Kolakovic, R., Viitala, T., Ihalainen, P. et al. (2013). Printing technologies in fabrication of drug delivery systems. Expert Opinion on Drug Delivery 10 (12): 1711–1723.
- Yu, D.G., Zhu, L.-M., Branford-White, C.J., and Yang, X.L. (2008). Three-dimensional printing in pharmaceutics: promises and problems. Journal of Pharmaceutical Sciences 97 (9): 3666–3690.
- Prasad, L.K. and Smyth, H. (2016). 3D Printing technologies for drug delivery: a review. Drug Development and Industrial Pharmacy 42 (7): 1019–1031.
- Goole, J. and Amighi, K. (2016). 3D printing in pharmaceutics: A new tool for designing customized drug delivery systems. International Journal of Pharmaceutics 499 (1–2): 376–394.
-
Sandler, N. and Preis, M. (2016). Printed drug-delivery systems for improved patient treatment. Trends in Pharmacological Sciences
37 (12): 1070–1080.
10.1016/j.tips.2016.10.002 Google Scholar
-
Alhnan, M.A., Okwuosa, T.C., Sadia, M. et al. (2016). Emergence of 3D printed dosage forms: opportunities and challenges. Pharmaceutical Research
33 (8): 1817–1832.
10.1007/s11095-016-1933-1 Google Scholar
- de Gans, B.J., Duineveld, P.C., and Schubert, U.S. (2004). Inkjet printing of polymers: state of the art and future developments. Advanced Materials 16 (3): 203–213.
- Sandler, N., Määttänen, A., Ihalainen, P. et al. (2011). Inkjet printing of drug substances and use of porous substrates-towards individualized dosing. Journal of Pharmaceutical Sciences 100 (8): 3386–3395.
- Aronson, J.K. (2006). Polypharmacy, appropriate and inappropriate. British Journal of General Practice 56 (528): 484–485.
- WHO (2002). Secondary prevention of noncommunicable diseases in low-and middle-income countries through community-based and health service interventions: World Health Organization-Wellcome Trust meeting report, 1–3 August 2001. Geneva: World Health Organization.
- Wald, N.J. and Law, M.R. (2003). A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (7404): 1419.
-
Bramlage, P., Sims, H., Minguet, J., and Ferrero, C. (2017). The polypill: an effective approach to increasing adherence and reducing cardiovascular event risk. European Journal of Preventive Cardiology
24 (3): 297–310.
10.1177/2047487316674817 Google Scholar
- Wening, K. and Breitkreutz, J. (2011). Oral drug delivery in personalized medicine: unmet needs and novel approaches. International Journal of Pharmaceutics 404 (1–2): 1–9.
- Tamargo, J., Castellano, J.M., and Fuster, V. (2015). The Fuster-CNIC-Ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention. International Journal of Cardiology 201: S15–S23.
- Guglietta, A. and Guerrero, M. (2009). Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nature Clinical Pratice Cardiovascular Medicine 6 (2): 112.
- Goyanes, A., Buanz, A.B., Basit, A.W., and Gaisford, S. (2014). Fused-filament 3D printing (3DP) for fabrication of tablets. International Journal of Pharmaceuticals 476 (1–2): 88–92.
- Ventola, C.L. (2014). Medical applications for 3D printing: current and projected uses. Pharmacy and Therapeutics 39 (10): 704.
- Skowyra, J., Pietrzak, K., and Alhnan, M.A. (2015). Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing. European Journal of Pharmaceutical Sciences 68: 11–17.
- Raijada, D., Genina, N., Fors, D. et al. (2013). A step toward development of printable dosage forms for poorly soluble drugs. Journal of Pharmaceutical Sciences 102 (10): 3694–3704.
- Markarian J. (2016). FDA and the emerging technology of 3D printing, vol. 36. http://www.pharmtech.com/fda-and-emerging-technology-3d-printing (accessed 09 July 2018).
- Khaled, S.A., Burley, J.C., Alexander, M.R. et al. (2015). 3D printing of tablets containing multiple drugs with defined release profiles. International Journal of Pharmaceutics 494 (2): 643–650.
- Vakili, H., Kolakovic, R., Genina, N. et al. (2015). Hyperspectral imaging in quality control of inkjet printed personalised dosage forms. International Journal of Pharmaceutics 483 (1–2): 244–249.
- Katstra, W., Palazzolo, R., Rowe, C. et al. (2000). Oral dosage forms fabricated by Three Dimensional Printing™. Journal of Controlled Release 66 (1): 1–9.
-
Yu, D.-G., Branford-White, C., Yang, Y.-C. et al. (2009). A novel fast disintegrating tablet fabricated by three-dimensional printing. Drug Development and Industrial Pharmacy
35 (12): 1530–1536.
10.3109/03639040903059359 Google Scholar
- Hsiao, W.-K., Lorber, B., Reitsamer, H., and Khinast, J. (2018). 3D printing of oral drugs: a new reality or hype? Expert Opinion on Drug Delivery 15 (1): 1–4.
- Crump, S.S. (1992). Apparatus and method for creating three-dimensional objects. Google Patents US5121329A.
- Jin, Y.-a., Li, H., He, Y., and Fu, J.-z. (2015). Quantitative analysis of surface profile in fused deposition modelling. Additive Manufacturing 8: 142–148.
- Mohanty, S., Larsen, L.B., Trifol, J. et al. (2015). Fabrication of scalable and structured tissue engineering scaffolds using water dissolvable sacrificial 3D printed moulds. Materials Science and Engineering: C 55: 569–578.
- Chia, H.N. and Wu, B.M. (2015). Recent advances in 3D printing of biomaterials. Journal of Biological Engineering 9 (1): 4.
- Pietrzak, K., Isreb, A., and Alhnan, M.A. (2015). A flexible-dose dispenser for immediate and extended release 3D printed tablets. European Journal of Pharmaceutics and Biopharmaceutics 96: 380–387.
- Melocchi, A., Parietti, F., Maroni, A. et al. (2016). Hot-melt extruded filaments based on pharmaceutical grade polymers for 3D printing by fused deposition modeling. International Journal of Pharmaceutics 509 (1–2): 255–263.
- T. Huang, S. Wang, and K. He (eds.) (2015). Quality control for fused deposition modeling based additive manufacturing: current research and future trends. In: Reliability Systems Engineering (ICRSE), 2015 First International Conference on 2015. Beijing: IEEE.
- Goyanes, A., Buanz, A.B., Hatton, G.B. et al. (2015). 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets. European Journal of Pharmaceutics and Biopharmaceutics 89: 157–162.
- B. Vasudevarao, D.P. Natarajan, M. Henderson, and A. Razdan (eds.) (2000). Sensitivity of RP surface finish to process parameter variation. In: Solid Freeform Fabrication Proceedings. Austin, TX: University of Texas.
- R. Weeren, M. Agarwala, V. Jamalabad et al. (eds.) (1995). Quality of parts processed by fused deposition. In: Proceedings of the Solid Freeform Fabrication Symposium. Austin, TX: University of Texas.
-
Zhang, B., Seong, B., Nguyen, V., and Byun, D. (2016). 3D printing of high-resolution PLA-based structures by hybrid electrohydrodynamic and fused deposition modeling techniques. Journal of Micromechanics and Microengineering
26 (2): 025015.
10.1088/0960-1317/26/2/025015 Google Scholar
- Goyanes, A., Chang, H., Sedough, D. et al. (2015). Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing. International Journal of Pharmaceutics 496 (2): 414–420.
- Alhijjaj, M., Belton, P., and Qi, S. (2016). An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing. European Journal of Pharmaceutics and Biopharmaceutics 108: 111–125.
- Aho, J., Boetker, J.P., Baldursdottir, S., and Rantanen, J. (2015). Rheology as a tool for evaluation of melt processability of innovative dosage forms. International Journal of Pharmaceutics 494 (2): 623–642.
- Shah, S., Maddineni, S., Lu, J., and Repka, M.A. (2013). Melt extrusion with poorly soluble drugs. Internatinal Journal of Pharmaceutics 453 (1): 233–252.
-
Zhang, J., Feng, X., Patil, H. et al. (2017). Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Inteernational Journal of Pharmaceutics
519 (1-2): 186–197.
10.1016/j.ijpharm.2016.12.049 Google Scholar
- Okwuosa, T.C., Stefaniak, D., Arafat, B. et al. (2016). A lower temperature FDM 3D printing for the manufacture of patient-specific immediate release tablets. Pharmaceutical Research 33 (11): 2704–2712.
- Sadia, M., Sośnicka, A., Arafat, B. et al. (2016). Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets. International Journal of Pharmaceutics 513 (1–2): 659–668.
- Sadia, M., Arafat, B., Ahmed, W. et al. (2018). Channelled tablets: an innovative approach to accelerating drug release from 3D printed tablets. Journal of Controlled Release 269: 355–363.
- Solanki, N.G., Tahsin, M., Shah, A.V., and Serajuddin, A.T. (2018). Formulation of 3D printed tablet for rapid drug release by fused deposition modeling: screening polymers for drug release, drug-polymer miscibility and printability. Journal of Pharmaceutical Sciences 107 (1): 390–401.
- Lipson, H. and Kurman, M. (2013). Fabricated: The New World of 3D Printing. Wiley.
- US-FDA (2004). Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance .
- Cerniglia, D., Scafidi, M., Pantano, A., and Rudlin, J. (2015). Inspection of additive-manufactured layered components. Ultrasonics 62: 292–298.
- Alhijjaj, M., Reading, M., Belton, P., and Qi, S. (2015). Thermal analysis by structural characterization as a method for assessing heterogeneity in complex solid pharmaceutical dosage forms. Analytical Chemistry 87 (21): 10848–10855.
- US-FDA (2000). Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, 83041–83063.
